The Endexo platform is labeled as an additive technology intended to enhance the biocompatibility of medical devices that come into contact with blood, tissue or other biological fluids. Toronto-based Interface Biologics designed Endexo to reduce the risk of blood clots and suppress bacterial adhesion and biofilm formation on devices, which can cause infections.
Evonik (Essen, Germany) said it believes the purchase will strengthen its portfolio of biomaterials and application technology services. Several medtech companies license Endexo technology for use in the cardiovascular space, as well in as other disciplines. Some products that use Endexo are commercially available, while others are involved in clinical trials.
The companies did not disclose additional terms of the acquisition.
“We are excited to onboard the Endexo technology in our portfolio.” Evonik Health Care SVP & general manager Jean-Luc Herbeaux said in a news release. “Endexo expands our ability to serve as a development partner and solution provider to medical device companies worldwide. The team of Interface Biologics has done an exemplary job developing this innovative technology and bringing it to market. We look forward to applying our global business development capabilities and technical prowess to further expand the geographic and application footprint of Endexo.”
“We have been working closely with Evonik on joint development opportunities over the last few years,” added Tom Reeves, president & CEO of Interface Biologics. “I am confident that the combination of the Endexo technology platform and the technical, commercial and financial resources of Evonik will enable the rapid acceleration of the business across broad sectors of the medical device market.”